Table 2. Results of meta-analysis for rs9277535 polymorphism with HBV infection outcomes.
| Overall and subgroups analyses | No. of data sets | No. of cases/controls | A vs. G allele |
AG vs. GG |
AA vs. GG |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OR (95% CI) | P(Z) | P(Q) | I2 (%) | OR (95% CI) | P(Z) | P(Q) | I2 (%) | OR (95% CI) | P(Z) | P(Q) | I2 (%) | |||
| HBV Infection (All) | 32 | 22065/23500 | 0.60 (0.57–0.63) | <10−5 | <10−5 | 66.1 | 0.56 (0.52–0.60) | <10−5 | 0.01 | 40.7 | 0.39 (0.35–0.43) | <10−5 | 0.01 | 40.6 |
| Asian | 30 | 21099/22694 | 0.59 (0.56–0.62) | <10−5 | <10−5 | 59.6 | 0.56 (0.52–0.60) | <10−5 | 0.009 | 43.6 | 0.38 (0.35–0.42) | <10−5 | 0.02 | 39.0 |
| Non-Asians | 2 | 966/806 | 0.85 (0.73–0.99) | 0.04 | 0.57 | 0 | 0.62 (0.41–0.94) | 0.02 | 0.32 | 0 | 0.59 (0.39–0.89) | 0.01 | 0.35 | 0 |
| GWAS | 6 | 2917/5947 | 0.57 (0.48–0.67) | <10−5 | <10−5 | 80.9 | 0.49 (0.38–0.63) | <10−5 | 0.001 | 77.6 | 0.38 (0.28–0.53) | <10−5 | 0.01 | 69.9 |
| Replication study | 26 | 19148/17553 | 0.60 (0.57–0.64) | <10−5 | <10−5 | 61.7 | 0.57 (0.54–0.61) | <10−5 | 0.22 | 17.4 | 0.39 (0.35–0.43) | <10−5 | 0.06 | 32.7 |
| Large studies | 17 | 17211/15611 | 0.64 (0.59–0.68) | <10−5 | <10−5 | 70.1 | 0.60 (0.57–0.64) | <10−5 | 0.29 | 15.0 | 0.43 (0.38–0.48) | <10−5 | 0.03 | 45.5 |
| Small studies | 15 | 4854/7889 | 0.54 (0.51–0.58) | <10−5 | 0.16 | 27.1 | 0.49 (0.44–0.54) | <10−5 | 0.24 | 19.3 | 0.32 (0.28–0.37) | <10−5 | 0.77 | 0 |
| HBV Clearance (All) | 25 | 7753/17089 | 1.54 (1.43–1.66) | <10−5 | <10−4 | 62.8 | 1.64 (1.50–1.79) | <10−5 | 0.08 | 30.7 | 2.31 (1.99–2.67) | <10−5 | 0.003 | 50.4 |
| Asian | 24 | 7451/16324 | 1.57 (1.46–1.68) | <10−5 | 0.001 | 55.6 | 1.65 (1.51–1.80) | <10−5 | 0.10 | 29.0 | 2.37 (2.06–2.73) | <10−5 | 0.02 | 42.3 |
| Non-Asians | 1 | 302/765 | 1.02 (0.82–1.26) | 0.85 | NA | NA | 1.08 (0.64–1.81) | 0.78 | NA | NA | 1.07 (0.65–1.77) | 0.78 | NA | NA |
| GWAS | 1 | 185/181 | 1.95 (1.42–2.69) | <10−5 | NA | NA | 2.65 (1.68–4.17) | <10−5 | NA | NA | 2.48 (1.28–4.82) | 0.007 | NA | NA |
| Replication study | 24 | 7568/16908 | 1.53 (1.41–1.65) | <10−5 | <10−5 | 62.7 | 1.60 (1.48–1.74) | <10−5 | 0.18 | 21.6 | 2.30 (1.98–2.69) | <10−5 | 0.002 | 52.5 |
| Large studies | 10 | 4443/12359 | 1.47 (1.36–1.60) | <10−5 | 0.04 | 50.1 | 1.52 (1.38–1.68) | <10−5 | 0.22 | 25.3 | 2.12 (1.78–2.54) | <10−5 | 0.04 | 51.4 |
| Small studies | 15 | 3310/4730 | 1.61 (1.40–1.85) | <10−5 | <10−5 | 67.1 | 1.82 (1.59–2.08) | <10−5 | 0.36 | 8.7 | 2.52 (1.99–3.17) | <10−5 | 0.04 | 44.7 |
| AsC | 6 | 1751/2706 | 0.98 (0.87–1.09) | 0.66 | 0.33 | 13.9 | 0.97 (0.84–1.12) | 0.65 | 0.93 | 0 | 1.04 (0.71–1.52) | 0.85 | 0.06 | 53.1 |
| HCC development | 8 | 4398/7358 | 1.03 (0.97–1.09) | 0.35 | 0.59 | 0 | 0.92 (0.84–1.02) | 0.10 | 0.93 | 0 | 1.11 (0.95–1.29) | 0.19 | 0.66 | 0 |
NA: not available; AsC: asymptomatic HBsAg carrier; HCC: hepatocellular carcinoma.